AG
ALNY icon

Ascent Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ascent Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-627
Closed -$207K – 809
2026
Q1 		$207K Sell
627
-168
-21% -$57.2K 0.01% 722
2025
Q4 		$316K Buy
795
+171
+27% +$75.7K 0.01% 589
2025
Q3 		$284K Sell
624
-122
-16% -$49.7K 0.01% 616
2025
Q2 		$243K Sell
746
-3
-0.4% -$830 0.01% 634
2025
Q1 		$202K Buy
+749
New +$192K 0.01% 665

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ascent Group's ALNY Position: Q2 2026 in Review

Ascent Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 627 shares — an estimated $207K sold.

Ascent Group first reported a position in ALNY in Q1 2025 and held it in 5 quarters. The position peaked at $316K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ascent Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ascent Group sold 627 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Ascent Group first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Ascent Group's Alnylam Pharmaceuticals position peaked at $316K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.